For decades, medicine focused on treating the diseases that come with age. Now, a handful of countries are chasing something bigger: slowing aging itself, right down at the cellular level. It’s a mix of genetics, big data, and biotech, and it’s moving faster than most people realize.
The United States is still leading the charge. Harvard geneticist George Church has spent years developing gene therapies aimed at multiple aging pathways at once, and companies like Rejuvenate Bio have shown that gene therapy can extend lifespan and rejuvenate tissue in older mice. Human trials exploring similar ideas, including approaches inspired by Yamanaka factors, which can nudge cells back toward a more youthful state, are starting to take shape.
Elsewhere, the momentum is just as real. Singapore’s Centre for Healthy Longevity is turning lab research into real treatments. China is pouring money into AI-assisted drug discovery and regenerative medicine. Japan continues to do foundational work in cellular reprogramming. And in Europe, projects like Genomics England and Finland’s FinnGen are combining genome sequencing with health records on a massive scale, helping researchers understand why some people age differently than others.
The United Arab Emirates has also become a name worth knowing in this space. Its Emirati Genome Program has now sequenced close to a million genomes, roughly 80% of its citizen population, with a stated goal of reaching everyone. Even Church himself has pointed to this as a reason to watch the UAE closely: on a recent podcast appearance, he noted that the country’s speed in sequencing and adopting genomic technology could give it a real head start in areas like disease prevention and personalized medicine, especially compared to the slower pace of rollout in the US. That dataset is now feeding research into metabolic disease, heart health, and neurodegeneration, the kinds of conditions that shape how well, not just how long, we age. Abu Dhabi has also become a gathering point for the field, hosting events like the Healthy Longevity Symposium at Khalifa University.
Clinics in Dubai and Abu Dhabi now offer regenerative and gene-based treatments, drawing people interested in newer longevity approaches. It’s a fast-growing corner of the region’s healthcare sector, though still young compared to more established biotech hubs, and how it matures, both scientifically and in terms of oversight, is worth watching.
There are real questions still to work through: how these therapies get regulated, whether they’ll be affordable for the average person, and how we think about the ethics of extending healthy years. But the direction is clear. Aging research is shifting from managing decline to actively restoring function, and the countries investing early, and moving quickly on adoption, may shape what “healthy aging” looks like for the rest of us.
